Our Products

GRAN^® is a protein produced by genetic recombination technology. It works to selectively increase the count of a type of white cell called neurotrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It also acts to relieve congenital neutropenia or neutropenia occurring after hematopoietic stem-cell transplantation (such as bone-marrow transplants). In 2000 it received additional approval for application to PBSCT (peripheral blood stem cell transfusion) mobilization.

NESP^® is a new anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO). In comparison to previous erythropoietin preparations, it exhibits a sustained increase of erythrocytes. As such, it has the vital characteristic of correcting anemia with smaller doses than had been required previously.

ESPO^® is a glycoprotein, human erythropoietin, produced by using the technology of genetic recombination. Its specific pharmacological effect of increasing erythrocytes allows it to act as an anemia-relieving treatment for dialysis patients. In 1995 it was further adapted to the treatment of anemia found in premature infants, renal anemia during CAPD (continuous ambulatory peritoneal dialysis) and before dialysis treatment, as well as for autologous blood transfusion.

CONIEL^® is the nation's first long-acting calcium antagonist (generic name hydrochloride benidipine) in Japan and effective against both hypertension and angina pectoris. It has been demonstrated that this drug has a high affinity for the vascular smooth muscle cell membrane and that its antihypertensive and other pharmacological effects are sustained over a long period with no correlation with blood concentrations of the drug.

REGPARA^® is a new class of agent for the treatment of secondary hyperparathyroidism. REGPARA^® acts on parathyroid calcium receptor directly and suppresses parathyroid hormone secretion, while simultaneously lowering serum calcium and phosphorus levels.

ALLELOCK^® is a medicine for patients with all types of allergies (generic name olopatadine hydrochloride). It exhibits potent and selective antihistamine activity, and suppresses various symptoms of allergies by widely inhibiting the factors involved in allergic reactions. It relieves the three major symptoms of pollinosis or allergic rhinitis (sneezing, nasal discharge and congestion), as well as itching associated with chronic urticaria and skin diseases.
The active ingredient of the antiallergic eye drops Patanol^® is the same olopatadine hydrochloride. The product was first developed, manufactured and sold overseas by the Alcon Group. It is approved for sale in over eighty countries worldwide including Japan.

DEPAKENE^® is an antiepileptic agent with sodium valproate as its active ingredient that has proved to be highly effective administered alone. It comes in various dosage forms to meet different clinical needs. In addition to treating various types of epilepsy and behavioral or personality disorders resulting from epilepsy, it is also used to treat mania and manic depression.
TOPINA^® is an antiepileptic agent whose active ingredient is topiramate. Administered in combination with other medicines, it is effective against epilepsy with partial seizures (including secondary generalized seizures), against which other treatments have not yet been shown to be fully effective. It is highly effective in enhancing the quality of life of intractable epilepsy patients.